LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29

LIXTE Biotechnology (Nasdaq: LIXT) will participate at the DealFlow Discovery Conference in Atlantic City, New Jersey on January 28-29, 2026.

Rhea-AI Summary

LIXTE Biotechnology (Nasdaq: LIXT) will participate at the DealFlow Discovery Conference in Atlantic City, New Jersey on January 28-29, 2026. CEO Geordan Pursglove is scheduled to hold one-on-one investor meetings at The Borgata Hotel, Casino & Spa. The company is clinical-stage and advancing LB-100, a PP2A inhibitor. Investors may register or request meetings via the conference registration page.

Argus Jan 20 session

-8.43% close to close Open Argus

Details

News Market Reaction – LIXT

In the Jan 20 session, LIXT declined 8.43%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -8.4% in the session following this news. A negative reaction despite the neutral na...

Analysis

The stock moved -8.4% in the session following this news. A negative reaction despite the neutral nature of a conference attendance announcement fits a pattern where certain operational updates, such as the $4.3 million offering and trial expansion in late 2025, were followed by modest declines. This type of move may reflect sensitivity to dilution history and ongoing funding needs. Past positive responses to strategic oncology updates suggest that future news flow could be more influential than conference participation alone.

Key Figures

Conference dates: January 28-29, 2026 Announcement date: January 20, 2026 Conference venue address: 1 Borgata Way

Conference dates

January 28-29, 2026

DealFlow Discovery Conference attendance

Announcement date

January 20, 2026

Press release publication date

Conference venue address

1 Borgata Way

Location of The Borgata Hotel, Casino & Spa

Historical Context

5 past events · Latest: Dec 23

5 events

1. Dec 23

   Trial expansion update

   24h Move

   -1.9%

   Ovarian clear cell cancer trial enrollment doubled from 21 to 42 patients.

2. Dec 18

   Equity offering

   24h Move

   -1.0%

   Registered direct offering to raise $4.3M via units and warrants.

3. Dec 08

   Oncology strategy shift

   24h Move

   +7.2%

   Acquisition of Liora Technologies and LiGHT radiotherapy platform.

4. Dec 03

   Platform expansion

   24h Move

   +3.5%

   Multi-modal oncology platform update and Liora acquisition details.

5. Dec 03

   Treatment amplifier focus

   24h Move

   +3.5%

   Progress update on LB-100 as amplifier and key partnerships.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

protein phosphatase 2A (PP2A)

1 terms

protein phosphatase 2A (PP2A) medical

"LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A)"

Protein phosphatase 2A (PP2A) is a naturally occurring enzyme that helps regulate cell activity by turning off or dialing down signaling proteins, acting like a molecular “brake” that keeps cell growth and cleanup processes in balance. Investors care because PP2A dysfunction is linked to cancer and other diseases, making it a target for drugs and diagnostics; therapies that restore or modulate PP2A activity can create commercial opportunity and affect the valuation of related biotech companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOCA RATON, Fla., Jan. 20, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), today announced the Company will participate at the DealFlow Discovery Conference in Atlantic City, New Jersey, January 28-29, 2026. Geordan Pursglove, LIXTE’s Chief Executive Officer, will conduct one-on-one meetings with investors during the conference.

The conference will be held at The Borgata Hotel, Casino & Spa, 1 Borgata Way. To register or schedule a one-on-one meeting, please visit https://dealflowdiscoveryconference.com/registration/

About LIXTE Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.

LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information about LIXTE can be found at www.lixte.com.

Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at www.lioratechnologies.com.

For more information about LIXTE, contact: 

info@lixte.com
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations pwinvestor@pondel.com
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will LIXTE (LIXT) attend the DealFlow Discovery Conference?

LIXTE will attend on January 28-29, 2026 in Atlantic City, New Jersey.

Who from LIXTE will meet investors at the DealFlow Discovery Conference?

Geordan Pursglove, LIXTE's CEO, will conduct one-on-one investor meetings.

Where is the DealFlow Discovery Conference being held for LIXTE meetings?

The conference is at The Borgata Hotel, Casino & Spa, 1 Borgata Way, Atlantic City, NJ.

How can investors schedule a one-on-one meeting with LIXTE at the conference?

Investors can register or request meetings via the conference registration page at https://dealflowdiscoveryconference.com/registration/.

What program is LIXTE advancing that investors may ask about at the conference?

LIXTE is advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A).

Is LIXTE a public company and what is its ticker symbol?

Yes. LIXTE is a clinical-stage public company trading on Nasdaq under the symbol LIXT.